Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP 980 · 1 trial · 1 indication
Pathologic complete response (pCR) was defined as the absence of invasive tumor cells in the breast tissue and in axillary lymph nodes, regardless of residual ductal carcinoma in situ (DCIS). Participants underwent a lumpectomy or mastectomy with sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND) within 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. The pathology evaluation of surgical specimens for pCR analysis was conducted by local laboratories at the study sites.
| Arm | Type | Description |
|---|---|---|
| ABP 980 | EXPERIMENTAL | Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase. Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase. |
| Trastuzumab | ACTIVE_COMPARATOR | Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase. Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase. After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase. |
| Name | Type | Description |
|---|---|---|
| ABP 980 | DRUG | ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles. |
| Trastuzumab | DRUG | Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles. |
| Paclitaxel | DRUG | Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care). |
| Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection | PROCEDURE | - |
Inclusion Criteria: * Females ≥ 18 years of age * Histologically confirmed invasive breast cancer * Planning for surgical resection of breast tumor and sentinel node or axillary lymph node resection * Planning neoadjuvant chemotherapy * HER2 positive disease * Measurable disease in the breast after...
Top 20 of 92 competitors
ABP 980 is an investigational small molecule being developed for the treatment of breast cancer. It is currently in Phase 3 clinical development, with one completed trial in women with HER2-positive early breast cancer.
ABP 980 is a small molecule that targets HER2, a protein involved in the growth of certain breast cancers. It is being studied as a potential treatment for HER2-positive early breast cancer.
ABP 980 is being developed by Amgen Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol AMGN.
ABP 980 is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy.
ABP 980 has one completed Phase 3 trial, NCT01901146, which evaluated its efficacy and safety compared with trastuzumab in women with HER2-positive early breast cancer. The trial enrolled 725 participants across multiple countries.
ABP 980 is not the same as trastuzumab, but it is being studied as a potential biosimilar to trastuzumab. The Phase 3 trial compared ABP 980 directly with trastuzumab in patients with HER2-positive early breast cancer.